Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherDrug Discovery and Translational Medicine

Opening of intermediate conductance Ca2+-activated K+ channels in C2C12 skeletal muscle cells increases the myotube diameter via the Akt/mTOR pathway

Yuzo Iseki, Yuko Ono, Chihiro Hibi, Shoko Tanaka, Shunya Takeshita, Yuko Maejima, Junko Kurokawa, Masahiro Murakawa, Kenju Shimomura and Kazuho Sakamoto
Journal of Pharmacology and Experimental Therapeutics December 29, 2020, JPET-AR-2020-000290; DOI: https://doi.org/10.1124/jpet.120.000290
Yuzo Iseki
1Department of Anesthesiology, Fukushima Medical University, School of Medicine, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuko Ono
2Department of Disaster and Emergency Medicine, Kobe University, Graduate School of Medicine, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chihiro Hibi
3Department of Bio-Informational Pharmacology, University of Shizuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shoko Tanaka
4Department of Bioregulation and Pharmacological Medicine, Fukushima Medical University, School of Medicine, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shunya Takeshita
5University of Shizuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuko Maejima
4Department of Bioregulation and Pharmacological Medicine, Fukushima Medical University, School of Medicine, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junko Kurokawa
5University of Shizuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masahiro Murakawa
1Department of Anesthesiology, Fukushima Medical University, School of Medicine, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenju Shimomura
4Department of Bioregulation and Pharmacological Medicine, Fukushima Medical University, School of Medicine, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuho Sakamoto
3Department of Bio-Informational Pharmacology, University of Shizuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kazuho Sakamoto
  • For correspondence: kazuho@u-shizuoka-ken.ac.jp
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The activation of potassium channels and following hyperpolarization in skeletal myoblasts is essential for myogenic differentiation. However, the effects of K+ channel opening in myoblasts on skeletal muscle mass are unclear. Our previous study revealed that pharmacological activation of intermediate conductance Ca2+-activated K+ channels (IKCa channels) increases myotube formation. In this study, we investigated the effects of DCEBIO, a KCa channel opener, on the mass of skeletal muscle. Application of DCEBIO to C2C12 cells during myogenesis increased the diameter of C2C12 myotubes in a concentration-dependent manner. This DCEBIO-induced hypertrophy was abolished by gene-silencing of IKCa channels. However, it was resistant to 1 µM, but sensitive to 10 µM TRAM-34, a specific IKCa channel blocker. Furthermore, DCEBIO reduced the mitochondrial membrane potential by opening IKCa channels. Therefore, DCEBIO should increase myotube mass by opening of IKCa channels distributed in mitochondria. Pharmacological studies revealed that mitochondrial reactive oxygen species (mitoROS), Akt, and mTOR are involved in DCEBIO-induced myotube hypertrophy. An additional study demonstrated that DCEBIO-induced muscle hypertrophic effects are only observed when applied in the early stage of myogenic differentiation. In an in vitro myotube inflammatory atrophy experiment, DCEBIO attenuated the reduction of myotube diameter induced by endotoxin. Thus, we concluded that DCEBIO increases muscle mass by activating the IKCa channel/mitoROS/Akt/mTOR pathway. Our study suggests the potential of DCEBIO in the treatment of muscle wasting diseases.

Significance Statement Our study shows DCEBIO, a small molecule opener of Ca2+ activated K+ channel, increased muscle diameter via mitochondria ROS/Akt/mTOR pathway. And DCEBIO overwhelms C2C12 myotube atrophy induced by endotoxin challenge. Our report should inform novel role of K+ channel in muscle development and novel usage of K+ channel opener such as for the treatment of muscle wasting diseases.

  • AKT
  • calcium-activated potassium channels
  • endotoxins
  • mitochondria
  • mTOR
  • skeletal muscle
  • Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 376 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 376, Issue 2
1 Feb 2021
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Opening of intermediate conductance Ca2+-activated K+ channels in C2C12 skeletal muscle cells increases the myotube diameter via the Akt/mTOR pathway
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherDrug Discovery and Translational Medicine

IKCa channels in muscle hypertrophy

Yuzo Iseki, Yuko Ono, Chihiro Hibi, Shoko Tanaka, Shunya Takeshita, Yuko Maejima, Junko Kurokawa, Masahiro Murakawa, Kenju Shimomura and Kazuho Sakamoto
Journal of Pharmacology and Experimental Therapeutics December 29, 2020, JPET-AR-2020-000290; DOI: https://doi.org/10.1124/jpet.120.000290

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherDrug Discovery and Translational Medicine

IKCa channels in muscle hypertrophy

Yuzo Iseki, Yuko Ono, Chihiro Hibi, Shoko Tanaka, Shunya Takeshita, Yuko Maejima, Junko Kurokawa, Masahiro Murakawa, Kenju Shimomura and Kazuho Sakamoto
Journal of Pharmacology and Experimental Therapeutics December 29, 2020, JPET-AR-2020-000290; DOI: https://doi.org/10.1124/jpet.120.000290
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Blebbistatin scaffold is ideal for drug development
  • Cx43 Activity and Modulation in the Myometrium
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics